Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Journey MedicalDERM -4.57%61 3-Year Book Growth Rate is 7.10% as of Jun. 2026, which is 42% below its 10-year median of 12.20. GuruFocus rates DERM with a GF Score™ of 61/100 and a GF Value™ of $5.18 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 912 Drug Manufacturers companies, Journey Medical ranks better than 59.43% on this metric.
During the past 12 months, Journey Medical's average Book Value per Share Growth Rate was 41.60% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 7.10% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 0.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 7 years, the highest 3-Year average Book Value per Share Growth Rate of Journey Medical was 76.50% per year. The lowest was -28.00% per year. And the median was 12.20% per year.
Journey Medical (NAS:DERM) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Journey Medical 3-Year Book Growth Rate Related Terms
DERM vs SIGA, ORGO, AKBA: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Journey Medical 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Journey Medical's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Journey Medical's 3-Year Book Growth Rate falls into.
Journey Medical 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 7.10% mean?
Journey Medical (DERM) has a 3-Year Book Growth Rate of 7.10% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Journey Medical and its competitors. This is 42% below median its historical median of 12.20. According to the industry distribution chart, Journey Medical ranks #370 out of 912 companies in the Drug Manufacturers industry, placing it in the top 40.6%.
Is Journey Medical's 3-Year Book Growth Rate too high?
Journey Medical's current 3-Year Book Growth Rate of 7.10% is 42% below median its 10-year median of 12.20. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.60. Journey Medical's value of 7.10% is 54.3% above this industry median. Based on the distribution chart, Journey Medical ranks #370 out of 912 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Journey Medical has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Journey Medical's 3-Year Book Growth Rate compare to SIGA and ORGO?
According to the Drug Manufacturers industry distribution chart, Journey Medical ranks #370 out of 912 companies for 3-Year Book Growth Rate. This puts Journey Medical in the upper half of its industry. The industry median 3-Year Book Growth Rate is 4.60. Journey Medical's value of 7.10% is 54.3% above this benchmark. While the company's 10-year median is 12.20 vs. the industry median of 4.60, Journey Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.60, based on 912 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Journey Medical's current 3-Year Book Growth Rate of 7.10% is 54.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Journey Medical and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Journey Medical's current 3-Year Book Growth Rate is 7.10%, which is 42% below median its own 10-year median of 12.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Journey Medical stock overvalued right now?
Based on GuruFocus' analysis, Journey Medical (DERM) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.18, compared to a current price of $6.99 — trading 34.9% above its estimated fair value. The current 3-Year Book Growth Rate is 7.10%, which is 42% below median its 10-year median of 12.20 and 54.3% above the Drug Manufacturers industry median of 4.60. Journey Medical's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Journey Medical (DERM), the current 3-Year Book Growth Rate is 7.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Journey Medical (DERM) Overvalued in 2026?
Based on GuruFocus' analysis, Journey Medical stock appears to be overvalued.
The current stock price of $6.99 is trading 34.9% above its estimated GF Value™ of $5.18.
GuruFocus considers Journey Medical to be Significantly Overvalued.
Key valuation signals for DERM:
3-Year Book Growth Rate: 7.10% (42% below median its 10-year median of 12.20)
GF Value™: $5.18 vs. price of $6.99 (34.9% above fair value)
Industry Position: 54.3% above the Drug Manufacturers median (#370 of 912)
No single metric tells the full story. See the DERM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
61GF Score
Get the complete analysis for DERM
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DERM has been successfully added to your 
